169 related articles for article (PubMed ID: 15044728)
21. Docking and 3D-QSAR investigations of pyrrolidine derivatives as potent neuraminidase inhibitors.
Sun J; Mei H
Chem Biol Drug Des; 2012 May; 79(5):863-8. PubMed ID: 22251826
[TBL] [Abstract][Full Text] [Related]
22. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
Finley JB; Atigadda VR; Duarte F; Zhao JJ; Brouillette WJ; Air GM; Luo M
J Mol Biol; 1999 Nov; 293(5):1107-19. PubMed ID: 10547289
[TBL] [Abstract][Full Text] [Related]
23. Protein-ligand binding affinity predictions by implicit solvent simulations: a tool for lead optimization?
Michel J; Verdonk ML; Essex JW
J Med Chem; 2006 Dec; 49(25):7427-39. PubMed ID: 17149872
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophore model of influenza neuraminidase inhibitors--a systematic review.
Gong JZ; Liu Y; Xu WF
Pharmazie; 2009 Oct; 64(10):627-32. PubMed ID: 19947162
[TBL] [Abstract][Full Text] [Related]
25. Optimal charges in lead progression: a structure-based neuraminidase case study.
Armstrong KA; Tidor B; Cheng AC
J Med Chem; 2006 Apr; 49(8):2470-7. PubMed ID: 16610790
[TBL] [Abstract][Full Text] [Related]
26. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs.
von Itzstein M; Dyason JC; Oliver SW; White HF; Wu WY; Kok GB; Pegg MS
J Med Chem; 1996 Jan; 39(2):388-91. PubMed ID: 8558506
[TBL] [Abstract][Full Text] [Related]
27. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
[TBL] [Abstract][Full Text] [Related]
28. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
Kar P; Knecht V
J Phys Chem B; 2012 May; 116(21):6137-49. PubMed ID: 22553951
[TBL] [Abstract][Full Text] [Related]
29. The conformational analysis and proton transfer of neuraminidase inhibitors: a theoretical study.
Yang Z; Yang G; Zu Y; Fu Y; Zhou L
Phys Chem Chem Phys; 2009 Nov; 11(43):10035-41. PubMed ID: 19865756
[TBL] [Abstract][Full Text] [Related]
30. Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfluenza virus type 1.
Nishino R; Ikeda K; Hayakawa T; Takahashi T; Suzuki T; Sato M
Bioorg Med Chem; 2011 Apr; 19(7):2418-27. PubMed ID: 21382718
[TBL] [Abstract][Full Text] [Related]
31. Identification of selective inhibitors for human neuraminidase isoenzymes using C4,C7-modified 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) analogues.
Zhang Y; Albohy A; Zou Y; Smutova V; Pshezhetsky AV; Cairo CW
J Med Chem; 2013 Apr; 56(7):2948-58. PubMed ID: 23530623
[TBL] [Abstract][Full Text] [Related]
32. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid.
Bossart-Whitaker P; Carson M; Babu YS; Smith CD; Laver WG; Air GM
J Mol Biol; 1993 Aug; 232(4):1069-83. PubMed ID: 8371267
[TBL] [Abstract][Full Text] [Related]
33. Binding free energies and free energy components from molecular dynamics and Poisson-Boltzmann calculations. Application to amino acid recognition by aspartyl-tRNA synthetase.
Archontis G; Simonson T; Karplus M
J Mol Biol; 2001 Feb; 306(2):307-27. PubMed ID: 11237602
[TBL] [Abstract][Full Text] [Related]
34. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.
Sun J; Cai S; Yan N; Mei H
Eur J Med Chem; 2010 Mar; 45(3):1008-14. PubMed ID: 19969399
[TBL] [Abstract][Full Text] [Related]
35. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
Gao L; Zu M; Wu S; Liu AL; Du GH
Bioorg Med Chem Lett; 2011 Oct; 21(19):5964-70. PubMed ID: 21843936
[TBL] [Abstract][Full Text] [Related]
36. 2-Deoxy-2,3-didehydro-N-acetylneuraminic acid analogues structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
Ikeda K; Sato K; Kitani S; Suzuki T; Maki N; Suzuki Y; Sato M
Bioorg Med Chem; 2006 Dec; 14(23):7893-7. PubMed ID: 16908163
[TBL] [Abstract][Full Text] [Related]
37. Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening.
Steindl T; Langer T
J Chem Inf Comput Sci; 2004; 44(5):1849-56. PubMed ID: 15446845
[TBL] [Abstract][Full Text] [Related]
38. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
[TBL] [Abstract][Full Text] [Related]
39. Structures of aromatic inhibitors of influenza virus neuraminidase.
Jedrzejas MJ; Singh S; Brouillette WJ; Laver WG; Air GM; Luo M
Biochemistry; 1995 Mar; 34(10):3144-51. PubMed ID: 7880809
[TBL] [Abstract][Full Text] [Related]
40. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
Li L; Li Y; Zhang L; Hou T
J Chem Inf Model; 2012 Oct; 52(10):2715-29. PubMed ID: 22998323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
